Close

GenKOre- Korea Creating Base-Editing Tech For Genetic Issues

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Smart Drug Delivery Systems Redefine Healthcare Innovation

Smart Drug Delivery Systems: Emerging Market Trends Driven by technical...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Adenine base editors were successfully created by GenKOre, a biotech startup in South Korea, using its unique hypercompact gene-editing method.

The hypercompact ABEs created by GenKOre are distinguished by their small size, ability to be delivered via an adeno-associated virus (AAV), and base-editing activity that is both selective and flexible and has been verified in vivo. Previous base-editing technology was created using a SpCas9 nuclease that is so large that it cannot be carried by AAV vectors that have a payload cap, and is therefore restricted to hepatic distribution. Through AAV delivery, this new base-editing method is anticipated to offer a range of in vivo therapy options for genetic illnesses.

To recruit a vast pool of talent for the creation of hypercompact ABEs-based gene therapy, GenKOre recently increased the size of its research facility in Seoul. The company is also looking for partnerships with academic institutions and pharmaceutical firms. Additionally, it is growing its ex vivo gene therapy business through strategic alliances with organisations that have a focus on immune cells and hematopoietic stem cells. Thus, ex vivo gene-editing treatments will be developed using the ABE platform.

Latest stories

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Smart Drug Delivery Systems Redefine Healthcare Innovation

Smart Drug Delivery Systems: Emerging Market Trends Driven by technical...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back